Enhancement of the Sensitivity of the Whole-Blood Gamma Interferon Assay for Diagnosis of Mycobacterium bovis Infections in Cattle

Michel Denis,1 D. Neil Wedlock,1 Allison R. McCarthy,1 Natalie A. Parlane,1 Paul J. Cockle,2 H. Martin Vordermeier,2 R. Glyn Hewinson,2 and Bryce M. Buddle1∗

AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand,1 and Veterinary Laboratory Agency, Weybridge, Surrey, United Kingdom2

Received 17 July 2007/Returned for modification 5 September 2007/Accepted 7 September 2007

In this study, we determined if the sensitivity of the currently available in vitro test to detect bovine tuberculosis could be enhanced by adding the following immunomodulators: interleukin-2 (IL-2); granulocyte-macrophage colony-stimulating factor (GM-CSF); antibodies neutralizing IL-10 and transforming growth factor β (TGF-β); mono-methyl-L-arginine, which blocks nitric oxide production; and l-methyl-tryptophan, which interferes with the indoleamine dioxygenase pathway. Blood was obtained from uninfected control cattle, experimentally infected cattle, cattle responding positively to the skin test in tuberculosis-free areas (false positives), and cattle naturally infected with Mycobacterium bovis from New Zealand and Great Britain. Gamma interferon (IFN-γ) responses to bovine purified protein derivative (PPD-b), avian purified protein derivative, and a fusion protein of ESAT-6 and CFP-10 were measured. Mono-methyl-L-arginine, l-methyl-tryptophan, or an antibody neutralizing TGF-β had minimal impact on IFN-γ production. IL-2 and GM-CSF promoted IFN-γ release whether antigen was present or not. In contrast, adding an antibody against IL-10 enhanced only antigen-specific responses. In particular, addition of anti-IL-10 to ESAT-6/CFP-10-stimulated blood cultures enhanced the test sensitivity. Furthermore, whole blood cells from field reactors produced substantial amounts of IL-10 upon stimulation with PPD-b or ESAT-6/CFP-10. Testing “false-positive” cattle from tuberculosis-free areas of New Zealand revealed that addition of anti-IL-10 did not compromise the test specificity. Therefore, the use of ESAT-6/CFP-10 with anti-IL-10 could be useful to detect cattle potentially infected with tuberculosis, which are not detected using current procedures.

The majority of cattle infected with Mycobacterium bovis develop a delayed-type hypersensitivity response, which is manifested as a positive response to intradermal injection with purified protein derivative (PPD) (13). This skin test, or an in vitro correlate, the whole-blood gamma interferon (IFN-γ) test (BOVIGAM; Prionics, Zurich, Switzerland), is used to screen for M. bovis infections and forms the cornerstone of the test-and-slaughter approach to tuberculosis control in New Zealand and other countries (reviewed in reference 11). Unfortunately, a proportion of cattle fail to develop an in vivo or in vitro responsiveness to PPD, despite being infected with tuberculosis (so-called anergic animals) (20). The presence of such a subset of cattle sometimes necessitates the slaughter of whole herds harboring such tuberculosis-infected cattle that escape standard testing. Based on data accumulated in human tuberculosis disease, we hypothesized that the failure of these cattle to develop a response to PPD is based in part on the release by “suppressive regulatory” T cells of immunosuppressive cytokines, such as interleukin-10 (IL-10) and transforming growth factor β (TGF-β), that block the release of the key cytokines (such as IFN-γ) that are involved in PPD responsiveness (4, 6, 7, 15, 22). Many infectious diseases, particularly chronic ones, such as tuberculosis, determine the emergence of a cascade of cytokines and cells that regulate the ongoing immune response. Cytokines that drive an efficient immune response are released by a subgroup of T cells that render animals more resistant to tuberculosis. Concomitantly, the developing immune response is also characterized by the emergence of cytokines that have anti-inflammatory activities, with IL-10 and TGF-β being two prototypical examples (6). This arm of the immune response is activated to prevent the continuous exuberant expression of proinflammatory mediators that irreversibly damage the infected tissues of infected animals. We hypothesized that anergic cattle are cattle in which that anti-inflammatory component has been recruited and prevents the expression of markers of immunity to tuberculosis, such as bovine PPD (PPD-b) responsiveness. Recent data in a bovine model of tuberculosis infection has suggested that there is an appreciable release of IL-10 associated with disease progression, strengthening the case for the involvement of IL-10 in PPD anergy (36). Recent work by Buza et al. has shown the potential of anti-IL-10 to augment production of antigen-specific IFN-γ in animals infected with Mycobacterium avium subsp. paratuberculosis (9). Similarly, it has been demonstrated that certain cells release significant levels of TGF-β in the course of bovine tuberculosis (18).

The failure to develop a response to PPD may also be linked to an enhanced activation profile of monocytes or macrophages, notably the release of high levels of reactive nitrogen and/or oxygen intermediates or prostaglandins (30). These molecules have the ability to reduce T-lymphocyte proliferation and/or cytokine release. An additional pathway that may lead to unresponsiveness in this system is the degradation of the amino acid tryptophan via the activation of an indoleamine-dioxygenase pathway in activated monocytes/macrophages, notably the release of high levels of reactive nitrogen and/or oxygen intermediates or prostaglandins (30). These molecules have the ability to reduce T-lymphocyte proliferation and/or cytokine release. An additional pathway that may lead to unresponsiveness in this system is the degradation of the amino acid tryptophan via the activation of an indoleamine-dioxygenase pathway in activated monocytes/macrophages, notably the release of high levels of reactive nitrogen and/or oxygen intermediates or prostaglandins (30). These molecules have the ability to reduce T-lymphocyte proliferation and/or cytokine release.
phages or dendritic cells, which oxidizes tryptophan to form kynurenine (14). The net effect of the activation of this pathway is to make tryptophan unavailable for proliferating T cells, leading to immunosuppression. Some evidence has been presented in mouse models of infection suggesting that the biological “recycling” of tryptophan leads to T-cell anergy (14). Another mechanism potentially involved in blunting a T-cell response includes an elevated release of the bactericidal and antiproliferative moiety nitric oxide (NO) by activated macrophages (5).

Finally, it is possible that the deficiency of a particular factor that promotes cellular responsiveness is responsible for in vitro anergy (25, 31). It was therefore deemed that an additional hypothesis to be tested should include the supplementation of cell cultures with key cytokines, such as IL-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), which may restore the responsiveness of cells from tuberculosis-infected animals to PPD.

The aim of this study was to test a range of immunomodulators that enhance IFN-γ or antibodies against factors that block the optimal release of IFN-γ. This research is focused on enhancing the sensitivity of the whole-blood IFN-γ test for bovine tuberculosis diagnosis.

**MATERIALS AND METHODS**

**Experimentally infected cattle.** In initial preliminary experiments, cattle experimentally infected with *M. bovis* were used to develop and expand the methodologies, allowing the identification of optimal doses and regimens of immunomodulators to enhance the responsiveness of immune cells to PPD. Nine Frisian cross female calves, approximately 9 months old, were obtained from tuberculosis-free accredited herds from an area of New Zealand where both farmed and feral animals were free of tuberculosis. Prior to the experiments, the cattle tested negative for reactivity to PPD from *M. bovis* (PPD-b) in the whole-blood IFN-γ assay (29). The calves were challenged intratracheally with 5 × 10³ CFU of virulent *M. bovis* as previously described (8). The cattle were grazed on pasture in a high-security containment unit. These animals tested positive in the comparative cervical skin test at 14 weeks after challenge. Blood samples for IFN-γ assay were collected 8 days after the skin test was read, and the animals were killed and necropsied 17 weeks after challenge. The nine challenged cattle all had gross tuberculous lesions in the lungs and pulmonary lymph nodes. In addition, *M. bovis* was cultured from the lesions, using techniques for bacterial isolation described previously (8). Animal ethics approval was granted for all animal experiments by the local ethics committees (Wallaceville Animal Ethics Committee and Veterinary Laboratory Agency [VLA], Weybridge, Surrey, United Kingdom Committee).

**Naturally infected cattle from New Zealand.** Six naturally infected cattle were identified on the basis of their responsiveness to a PPD skin test and in vitro IFN-γ responsiveness to PPD-b. On necropsy, these animals all had lung or lymph node lesions typical of bovine tuberculosis.

**Cattle from Great Britain.** Heparinized blood was obtained from skin test- and IFN-γ test-positive cattle from herds with multiple cases of culture-confirmed bovine tuberculosis. These cattle were held at VLA Weybridge under a project license granted by the United Kingdom Home Office under the Animal (Scientific Procedures) Act of 1986. Infection was confirmed by postmortem examination and culture.

**False-positive reactors.** Twenty-seven cattle were classified as false positive in the tuberculin test, based on their positive responsiveness in a caudal-fold tuberculin test but negative responsiveness in the ESAT-6/CFP10 IFN-γ test, and were from tuberculosis-free regions of New Zealand.

**Tuberculin skin testing.** A caudal-fold skin test was carried out by injecting a 0.1-ml volume containing 0.1 mg PPD-b (AgriQuality, Upper Hutt, New Zealand) intradermally in the caudal fold of the tail. Skin fold thickness was measured using calipers prior to injection and 72 h later. A positive delayed-type hypersensitivity response was recorded as any increase in skin fold thickness. A positive delayed-type hypersensitivity response was measured using calipers prior to injection and 72 h later. A positive delayed-type hypersensitivity response was as follows: PPD-b OD ≥ 5 mm more than that for PPD-a (New Zealand procedure) and ≥4 mm more than that for PPD-a (European Union procedure).

**Modified IFN-γ release in response to PPD-a, PPD-b, and ESAT-6/CFP10.** Heparinized blood was obtained from each animal and transported to AgResearch or VLA Weybridge overnight at ambient temperature. The blood cultures were set up at 18 to 24 h after blood collection and were cultured with PPD-a or PPD-b (24 μg/ml final concentration; Prionics, Schlieren-Zurich, Switzerland), ESAT-6/CFP10 (4 μg/ml final concentration; Statens Serum Institute, Copenhagen, Denmark), or phosphate-buffered saline (PBS), with and without added immunomodulators as shown in Table 1. The IFN-γ assay was performed as follows. PPDs or ESAT-6/CFP10 and the various immunomodulators were dispensed at 25 μl/well into sterile flat 96-well tissue culture plates. Two hundred and fifty microliters of whole blood was dispensed per well of the 96-well plates. The plates were incubated at 37°C and 5% CO₂ for 20 h and then centrifuged at 1,800 rpm for 15 min at room temperature. One hundred microliters of plasma from each well was collected and stored frozen at −20°C.

Neutralizing antibodies were purchased from Serotec (Oxford, United Kingdom). Our group had already validated the neutralizing activities of the anti-bodies used under the conditions described in different facets of our research activities. The optimal quantities of antibodies added to the various bovine cell cultures have been defined elsewhere (12; M. Denis, unpublished data). The chemicals used (mono-methyl-L-arginine [MMLA] and 1-methyl-tryptophan) were purchased from Sigma International (Saint Louis, MO); these products were cell culture grade, and the products had no toxicity or side effects on cells in vitro in control experiments. The bovine cytokines used here were produced in our laboratory (35). The recombinant cytokines were pure and were determined not to be contaminated by endotoxin. Our preliminary results identified the optimal doses of materials that were to be used in future experiments. All experimental conditions were tested in duplicate, and IFN-γ levels from the plasma samples were measured with the BOVIGAM test. Positive and negative controls were included in all plates, and there was very little variation between plates. The samples in the IFN-γ enzyme-linked immunosorbent assay (ELISA) were run in duplicate. Color change in the ELISA reaction was measured as optical density (OD) at 450 nm, and the results were expressed as OD units. For the diagnosis of bovine tuberculosis in New Zealand, the cutoff for the standard IFN-γ test was as follows: PPD-b OD – PPD-a OD ≥ 0.10 OD units. The cutoff for the ESAT-6/CFP10 IFN-γ assay was as follows: ESAT-6/CFP10 OD – PBS OD ≥ 0.04 OD units.

**Determination of IL-10 by ELISA.** Heparinized blood was collected, and peripheral blood mononuclear cells (PBMC) were prepared as described previously (28) and suspended in RPMI 1640 (Gibco, Paisley, United Kingdom) supplemented with 10% fetal calf serum (Sigma), penicillin-streptomycin, 2-mercaptoethanol, and nonessential amino acids (all from Sigma) as described elsewhere (28). A total of 2 × 10⁶ PBMC/well in 96-well plates were incubated for 48 h at 37°C in a humidified incubator with a 5% CO₂ atmosphere in the presence of PPD-b (10 μg/ml; VLA Weybridge, Addlestone, United Kingdom).

**TABLE 1. Culturing of blood with antigens and immunomodulators**

| Antigen | Immunomodulator |
|---------|-----------------|
| PPD-a, PPD-b, or ESAT-6/CFP10 | PBS¹ |
| PPD-a, PPD-b, or ESAT-6/CFP10 | Anti-IL-10 antibody² |
| PPD-a, PPD-b, or ESAT-6/CFP10 | Anti-TGF-β antibody³ |
| PPD-a, PPD-b, or ESAT-6/CFP10 | MMLA⁴ |
| PPD-a, PPD-b, or ESAT-6/CFP10 | Trypanphan⁵ |
| PPD-a, PPD-b, or ESAT-6/CFP10 | IL-2⁶ |
| PPD-a, PPD-b, or ESAT-6/CFP10 | GM-CSF⁷ |
| PBS | PBS⁸ |

¹ Positive control.  
² Neutralizing antibodies against IL-10 (1 μg/ml) (examines the role of endogenous IL-10 in PPD-b responsiveness).  
³ Neutralizing antibodies against TGF-β (10 μg/ml) (examines the role of TGF-β in PPD-b responsiveness).  
⁴ 5 mg/ml (examines the role of NO in PPD-b responsiveness).  
⁵ 5 mg/ml (examines the role of tryptophan degradation in PPD-b responsiveness).  
⁶ 10 U/ml (examines whether deficiency of IL-2 is involved in PPD-b responsiveness).  
⁷ 10 to 100 mg/ml (determines whether GM-CSF can enhance sensitivity to PPD-b).  
⁸ Negative control.
TABLE 2. Adding MMLA, tryptophan, or antibodies to TGF-β does not consistently modify PPD-b-driven IFN-γ release by PBMC of cattle experimentally infected with M. bovis.

| Animal | IFN-γ release driven by: | PPD-b | PPD-b + MMLA | PPD-b + anti-TGF-β | PPD-b + tryptophan | PBS |
|--------|--------------------------|-------|--------------|--------------------|--------------------|-----|
| 1      |                          | 1.56  | 1.51         | 1.88               | 1.61               | 0.05 |
| 2      |                          | 3.18  | 3.20         | 3.07               | 3.19               | 0.06 |
| 3      |                          | 2.86  | 2.73         | 3.03               | 2.68               | 0.09 |
| 4      |                          | 1.48  | 1.49         | 1.90               | 1.41               | 0.06 |
| 5      |                          | 2.10  | 1.91         | 2.49               | 1.95               | 0.06 |
| 6      |                          | 0.40  | 0.37         | 0.51               | 0.36               | 0.05 |
| 7      |                          | 0.76  | 0.75         | 1.06               | 0.74               | 0.11 |
| 8      |                          | 3.66  | 3.59         | 3.20               | 3.58               | 0.14 |
| 9      |                          | 1.85  | 1.70         | 1.77               | 1.63               | 0.07 |
| Uninfected |                  | 0.05  | 0.06         | 0.06               | 0.05               | 0.05 |

Uninfected cattle used as controls.

TABLE 3. Adding IL-2 or GM-CSF enhances IFN-γ release in response to antigens but also stimulates IFN-γ release without antigens in experimentally infected and uninfected cattle.

| Animal | IFN-γ release driven by: | PPD-b | PPD-b + GM-CSF | PPD-b + IL-2 | PPD-a | PPD-a + GM-CSF | PPD-a + IL-2 | IL-2 only | GM-CSF only | PBS |
|--------|--------------------------|-------|----------------|--------------|-------|----------------|--------------|-----------|-------------|-----|
| 1      |                          | 1.56  | 2.99           | 2.55        | 1.01  | 3.08           | 2.42         | 0.75      | 2.74        | 0.05 |
| 2      |                          | 3.18  | 2.97           | 3.31        | 2.21  | 3.01           | 3.15         | 0.48      | 3.10        | 0.06 |
| 3      |                          | 2.86  | 3.17           | 3.29        | 0.51  | 3.35           | 2.12         | 0.68      | 3.15        | 0.09 |
| 4      |                          | 1.48  | 3.41           | 3.37        | 0.42  | 3.47           | 2.27         | 0.79      | 3.33        | 0.06 |
| 5      |                          | 2.10  | 3.56           | 3.34        | 0.70  | 2.83           | 2.65         | 1.88      | 3.34        | 0.06 |
| 6      |                          | 0.40  | 3.45           | 1.51        | 0.18  | 3.38           | 1.24         | 0.66      | 2.59        | 0.05 |
| 7      |                          | 0.76  | 3.54           | 2.36        | 0.48  | 3.28           | 2.15         | 0.92      | 3.25        | 0.11 |
| 8      |                          | 3.66  | 3.41           | 3.77        | 2.17  | 2.59           | 3.41         | 0.07      | 2.60        | 0.14 |
| 9      |                          | 1.85  | 3.79           | 3.58        | 0.59  | 3.34           | 2.67         | 1.25      | 3.34        | 0.07 |
| Uninfected animal |                  | 0.05  | 2.28           | 0.13        | 0.06  | 2.45           | 0.15         | 0.14      | 2.45        | 0.05 |
| Uninfected animal B |                  | 0.11  | 0.04           | 2.00        | 0.16  | 0.04           | 1.83         | 1.50      | 0.04        | 0.05 |

a Animals 1 to 9 were infected with 5 x 10^3 CFU of M. bovis by the intratracheal route, and blood was sampled 15 weeks after infection.

b Results are expressed in OD units for duplicate wells.

c Uninfected cattle used as controls.

**RESULTS**

Impacts of various immunomodulators on IFN-γ release in response to PPD in cattle experimentally infected with M. bovis. Table 2 shows the impacts of adding MMLA, L-tryptophan, and a neutralizing antibody against TGF-β on the PPD-b-driven release of IFN-γ in nine experimentally infected cattle. All of the cattle showed a substantial release of IFN-γ in response to PPD-b alone. However, these three immunomodulators had minimal impacts on the release of IFN-γ from blood cells of infected cattle, and no significant increases in IFN-γ responses were observed.

**Effects of IL-2 or GM-CSF on IFN-γ release**. As seen in Table 3, adding GM-CSF or IL-2 enhanced the responses to both PPD-b and PPD-a in experimentally infected cattle but also led to marked IFN-γ release in one uninfected cow. Both IL-2 and GM-CSF in the absence of antigen also induced the release of significant amounts of IFN-γ in most cattle tested. Attempts to reduce the amounts of bovine cytokines to levels that would enhance PPD responsiveness without inducing IFN-γ release in the absence of antigens were inconclusive, as some cattle responded to very low concentrations of cytokines and responsiveness varied widely between cattle (data not shown). Variability across animals is a hallmark of diagnostic procedures for mycobacterial infections.

**Effects of a neutralizing antibody against IL-10 on IFN-γ release**. Table 4 shows that a neutralizing antibody against IL-10 enhanced the response to PPD-a and PPD-b in experimentally infected cattle. The addition of anti-IL-10 significantly increased responses to PPD-a (P < 0.001) and to PPD-b (P = 0.006). Anti-IL-10 antibody added alone (without antigen) did not result in significant release of IFN-γ by the blood cells of the cattle tested. Next, we examined the potential of neutralizing antibodies against IL-10 to enhance IFN-γ release by blood cells of naturally infected cattle. As shown in Table 5, anti-IL-10 markedly enhanced the PPD-b-driven IFN-γ release in four out of six naturally infected cattle (>0.100 OD unit increase).

Given that anti-IL-10 antibody enhanced both the PPD-a and the PPD-b responses in infected cattle, we elected to study
the potential of anti-IL-10 to enhance the IFN-γ response to the tuberculosis-specific antigens ESAT-6/CFP-10. The anti-IL-10 enhanced the response in all of the infected cattle ($P = 0.001$) and had no impact on the response of uninfected cattle (Table 6). We titrated the amounts of anti-IL-10 antibody required to enhance the IFN-γ response in this test and found that anti-IL-10 antibody amounts of 0.1 μg/ml were sufficient to enhance the ESAT-6/CFP-10 IFN-γ response in experimentally infected cattle (data not shown).

**Impact of anti-IL-10 on spontaneous release of IFN-10 in false-positive cattle from tuberculosis-free areas testing positive for PPD.** False-positive cattle were tested for their responsiveness to anti-IL-10 alone to ascertain if the antibody alone or in the presence of ESAT-6/CFP-10 could lead to spontaneous IFN-γ release. Twenty-seven cattle that were identified as false positives, i.e., that showed a positive skin test reaction but were located in a tuberculosis-free area of New Zealand, were tested for their responsiveness to the ESAT-6/CFP-10 plus anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10. Only one animal showed a positive response, which was just above the cutoff of 0.040 OD units, to ESAT-6/CFP-10 anti-IL-10.

**Table 5. Adding a neutralizing antibody against IL-10 enhances the PPD-b-driven IFN-γ release in some naturally infected cattle.**

| Animal* | IFN-γ release driven byb: | Anti-IL-10 only PBS |
|---------|------------------------|---------------------|
| Uninfected | | |
| Animal A | 0.05 0.06 0.06 0.07 0.08 0.08 | 0.06 0.06 0.06 0.06 0.06 0.06 |
| Animal B | 0.11 0.04 0.16 0.04 0.04 0.05 | 0.08 0.04 0.07 0.04 0.07 0.05 |

* Animals 1 to 9 were infected with 5 × 10^5 CFU of M. bovis by the intratracheal route, and blood was sampled 15 weeks after infection.

b Results are expressed in OD units for duplicate wells.

The IFN-γ response of animal 10 was positive for ESAT-6/CFP-10 and anti-IL-10.

**Table 6. Adding a neutralizing antibody against IL-10 enhances the ESAT-6/CFP-10-driven IFN-γ release in most experimentally infected cattle.**

| Animal* | IFN-γ release driven byb: | ESAT-6/CFP-10 anti-IL-10 |
|---------|------------------------|------------------------|
| Uninfected | | |
| Animal A | 0.06 0.06 0.06 0.14 0.12 0.10 | 0.05 0.13 0.05 0.06 0.06 0.06 |
| Animal B | 0.08 0.04 0.07 0.04 0.07 0.05 | 0.08 0.04 0.07 0.04 0.07 0.05 |

* Animals 1 to 9 were infected with 5 × 10^5 CFU of M. bovis by the intratracheal route, and blood was sampled 15 weeks after infection.

b Results are expressed in OD units for duplicate wells.

The addition of anti-IL-10 to cultures containing either PBS or ESAT-6/CFP10 did not result in a significant increase in IFN-γ responses. Some representative results are shown in Table 7.

**Anti-IL-10 enhances the sensitivity of IFN-γ in field reactors from Great Britain.** Field reactor cattle were selected from farms with persistent culture-confirmed bovine tuberculosis in Great Britain to assess the reproducibility of the anti-IL-10 treatment in a different cattle population. In the first experiment, blood from 31 such cattle was stimulated with PPD-a, PPD-b, or the ESAT-6/CFP10 fusion protein in the absence or presence of IL-10-neutralizing antibodies. The results are shown in Fig. 1, and they confirm the New Zealand data sets, as significant increases in IFN-γ responses after stimulation with all three antigens were observed after IL-10 neutralization (Fig. 1, P values between 0.005 and 0.0002). No

**Table 7. Adding a neutralizing antibody against IL-10 in false-positive” cattle does not induce IFN-γ release with or without anti-IL-10.**

| Animal* | IFN-γ release driven byb: |
|---------|------------------------|
| Uninfected | | |
| Animal A | 0.174 0.091 0.166 0.122 |
| Animal B | 0.059 0.095 0.048 0.046 |
| 3 | 0.071 0.073 0.069 0.07 |
| 4 | 0.041 0.081 0.053 0.038 |
| 5 | 0.035 0.079 0.032 0.031 |
| 6 | 0.043 0.085 0.035 0.041 |
| 7 | 0.046 0.089 0.047 0.06 |
| 8 | 0.112 0.092 0.0126 0.117 |
| 9 | 0.082 0.087 0.085 0.093 |
| 10 | 0.044 0.039 0.044 0.086 |

* Representative data from 10 cattle that were false positive in the tuberculin skin test. The IFN-γ response of animal 10 was positive for ESAT-6/CFP10 anti-IL-10 compared to PBS (ESAT-6/CFP10 anti-IL-10 OD – PBS OD > 0.040).

b Results are expressed in OD units for duplicate wells.
increased IFN-γ was observed in cultures without antigens (not shown), thus confirming the antigen-specific effect of anti-IL-10 treatment. The specificity of the anti-IL-10 treatment was further confirmed by treating a subset of 10 blood samples with an isotype control antibody. This treatment had no effect on IFN-γ production (mean PPD-b-induced IFN-γ ± standard deviation [SD] without antibody, 1.091 ± 0.929; with isotype control antibody, 1.068 ± 0.943; mean PPD-a-induced IFN-γ ± SD without antibody, 0.166 ± 0.140; with isotype control, 0.149 ± 0.137; and mean ESAT6/CFP10 fusion protein-induced IFN-γ ± SD without antibody, 0.326 ± 0.328; with isotype control, 0.318 ± 0.335).

We next determined whether the IL-10 in these cultures was present in the plasma of the cattle tested before blood culture or whether it was produced during the culture period. Plasma was removed from heparinized blood samples by centrifugation, and the pellets containing red and white blood cells were resuspended in RPMI 1640, followed by culture with PPD-b, PPD-a, or ESAT6/CFP10 in the presence or absence of anti-IL-10. Anti-IL-10 treatment was able to enhance IFN-γ production in these cultures to the same degree as in the control cultures containing plasma, thus demonstrating that IL-10 was produced during the whole-blood incubation period (data not shown). Further, PPD-b- and ESAT-6/CFP10-specific release of IL-10 (Fig. 2A) and IFN-γ (Fig. 2B) were determined using PBMC isolated from 24 field reactor cattle. The data demonstrated that significant amounts of IL-10 were produced alongside strong IFN-γ responses after both ESAT-6/CFP10 and PPD-b stimulation (Fig. 2A).

**DISCUSSION**

In this work, we sought to examine experimental maneuvers that enhance the sensitivity of the BOVIGAM assay for experimentally infected cattle, as well as naturally infected cattle. Uninfected cattle were used as negative controls to assess the specificity of the measurements. We tested nine experimentally infected cattle. These cattle had been infected with *M. bovis* (5 × 10^3 CFU by the intratracheal route) 15 weeks prior to testing. Six naturally infected cattle were also tested. In addition, 31 field reactor cattle were studied in Great Britain. In both naturally infected and experimentally infected cattle from New Zealand, it was found that modifying the BOVIGAM test by supplementing the media with tryptophan or MMLA had little impact on the PPD-b-driven IFN-γ response. Similarly, adding a neutralizing antibody against TGF-β to PPD-stimulated cultures had minimal impact on IFN-γ production. Only results for PPD-b responses are shown in Results, as PPD-a responses were not affected by these modulators (data not shown). It was therefore concluded that the release of TGF-β or NO or activation of the indoleamine dioxygenase pathway is not involved in masking responsiveness to PPD in vitro in bovine cells. In separate studies, we have observed that both NO and TGF-β are produced and released during the course of bovine tuberculosis by blood cells responding to PPD-b (M. Denis and B. M. Buddle, unpublished observations). This suggests that these mediators are present during the in vitro IFN-γ BOVIGAM but do not have a major impact on IFN-γ release.

Supplementing the cultures with IL-2 or GM-CSF enhanced the IFN-γ production by most experimentally infected cattle, but this increase occurred for both PPD-a and PPD-b. GM-CSF and IL-2 did not appreciably enhance the PPD-b re-
sponses in cattle that had very high basal PPD-b responses (3 out of 10 animals). In addition, most unstimulated blood cultures supplemented with IL-2 and GM-CSF released significant levels of IFN-γ. Therefore, adding GM-CSF and IL-2 (at the doses tested here) to PPD-stimulated cultures enhances the sensitivity but decreases the specificity of the assay. Titration of cytokines to find an optimal level that would stimulate a PPD response without spontaneous IFN-γ release gave inconclusive results (data not shown).

When cells from infected cattle were stimulated with PPD-b in vitro, neutralizing IL-10 enhanced the IFN-γ release, showing that endogenous IL-10 is involved in down-regulating the IFN-γ release. It was shown that IL-10 neutralization had no significant impact in a group of naturally infected cattle with very high PPD-b responses (>3.0 OD units), suggesting that the PPD-b response in these cattle was maximal. Moreover, this increase occurred for both the responses to PPD-a and PPD-b, suggesting that the use of antigens unique to M. bovis should be considered.

Based on these observations, we measured the ESAT-6/CFP-10-driven IFN-γ release in whole blood of infected cattle and control uninfected cattle in the presence of the immunomodulators listed above. ESAT-6 and CFP-10 are dominant IFN-γ-inducing antigens of tuberculosis mycobacteria, and they are specific to tuberculosis, being absent from most environmental nontuberculous mycobacteria (33). We found that blocking IL-10 markedly enhanced the response to ESAT-6/CFP-10 in all nine of the experimentally infected cattle, but not in the two uninfected cattle used as controls.

Studies performed on field reactor cattle in Great Britain provided additional evidence that neutralizing IL-10 led to a substantial enhancement of the IFN-γ response by whole blood cells in response to ESAT-6/CFP-10. In addition, study of the whole blood cells from field reactors showed that substantial IL-10 was produced in response to both PPD-b and ESAT-6/CFP-10.

False-positive cattle are sometimes identified in tuberculous-free regions of New Zealand; specifically, some cattle known to be tuberculosis free respond positively to PPD-b in both the tuberculin test and BOVIGAM. In those cases, the blood cultures of the cattle are retested with the tuberculosis-specific antigens ESAT-6/CFP-10. If the currently available BOVIGAM test is to be modified, that approach must not compromise the ability of the test to uncover false positives. It is currently believed that these false positives arise because a subset of blood cells known as NK cells respond to mycobacterial antigens without any prior exposure (24). Our data presented here suggest that ESAT-6/CFP-10 with anti-IL-10 do not compromise the ability of this “specific antigen” to identify false positives. We did not find that neutralizing IL-10 led to a significant IFN-γ release by control uninfected cattle or in false positives from New Zealand in response to either ESAT-6 or CFP-10.

However, preliminary screening of large groups of tuberculin skin test-negative cattle has revealed that some cattle that produced IFN-γ in response to PPD-a also produced IFN-γ responses to ESAT-6/CFP-10, which were further amplified by the addition of anti-IL-10 (Denis and Buddle, unpublished). We are currently investigating this phenomenon to identify the mechanism(s) involved in these anomalous results in high-PPD-a-responding animals. This may be caused by exposure of these animals to environmental mycobacteria that express ESAT-6/CFP-10 (3, 34).

Although our data are strongly suggestive that IL-10 is produced by antigen-specific T cells, IL-10 could have been produced by monocytes/macrophages. The definition of the subset producing this cytokine was beyond the scope of this study and needs to be determined in future experiments. It is tempting to speculate that these cells belong to one of the IL-10-producing populations of regulatory T cells that have been described in other species (reviewed in reference 1). It is interesting, however, that despite the positive modulation of antigen-specific IFN-γ production after neutralizing IL-10, significant and strong IFN-γ responses occurred alongside IL-10 responses (Fig. 2A and B). It is therefore also possible that IL-10 is produced by Th1 cells, as described recently (2, 17), to limit the collateral damage caused by strong inflammatory responses, although this could also result in a curtailed Th1 response and failure to eliminate the pathogen.

In conclusion, neutralizing IL-10 enhances the sensitivity of the in vitro IFN-γ test for bovine tuberculosis and may offer an attractive option for testing anergic animals in the field. However, more work is required to fully ascertain the specificity of this procedure.

ACKNOWLEDGMENTS

We thank the National Disease Control Managers (New Zealand) for locating animals and the staff from Asure and AgriQuality for collection of blood samples from field animals. We thank G. W. de Lisle and his staff for providing blood from false-positive animals.

This work was contracted by the Animal Health Board (New Zealand), the Ministry of Agriculture and Forestry (New Zealand), and Defra (United Kingdom).

REFERENCES

1. Akbar, A. A., N. M. Vukanovic-Stiejc, L. S. Taams, and D. C. Macfallan. 2007. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat. Rev. Immunol. 7:231–237.
2. Anderson, C. F., M. Oukka, V. J. Kuchroo, and D. Sacks. 2002. CD4+/CD8+ Foxp3+ T cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204:285–297.
3. Arend, S. M., P. de Haas, E. Leyten, L. Rosenkrands, L. Rignot, P. Anderson, W. Mijs, J. T. van Dissel, and D. van Soolingen. 2005. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J. Infect. Dis. 191:1301–1310.
4. Aung, H., M. Wu, J. L. Johnson, C. S. Hirsch, and Z. Toossi. 2005. Bioactivation of latent transforming growth factor beta-1 by Mycobacterium tuberculosis in human mononuclear phagocytes. Scand. J. Immunol. 61:558–565.
5. Bingisser, R., P. A. R. Tilbrook, P. G. Holt, and U. R. Kee. 1998. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160:5729–5734.
6. Bonecini-Almeida, M. G., G. J. Ho, N. Boechat, R. C. Huard, S. Chitale, H. Doo, J. Geng, L. Rego, C. L. Lazzarini, A. L. Kritski, W. D. Johnson, Jr., T. A. McCaffrey, and J. R. Silva. 2004. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-β) and analysis of TGF-β receptors I and II in active tuberculosis. Infect. Immun. 72:2628–2634.
7. Boussiotis, V. A., E. Y. Tsai, E. J. Yunis, S. Thim, J. C. Delgado, C. C. Dascher, A. Berezovskaya, D. Rousset, J. M. Reyes, and A. E. Goldfeld. 2000. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105:1317–1325.
8. Buddle, B. M., D. Keen, A. Thomson, G. Jowett, A. R. McCarthy, J. Heslop, G. W. De Lisle, J. L. Stanford, and F. E. Aldwell. 1995. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res. Vet. Sci. 59:10–16.
9. Buza, J. J., H. Hikono, Y. Mori, R. Nagata, S. Hirayama, Aodon-Geril, A. M. Buza, J. J., H. Hikono, Y. Mori, R. Nagata, S. Hirayama, Aodon-Geril, A. M. Boussiotis, V. A., E. Y. Tsai, E. J. Yunis, S. Thim, J. C. Delgado, C. C. Dascher, A. Berezovskaya, D. Rousset, J. M. Reyes, and A. E. Goldfeld. 2000. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105:1317–1325.
with Mycobacterium avium subsp. paratuberculosis in experimentally infected cattle with paratuberculosis. Infect. Immun. 72:2425–2428.

10. Reference deleted.

11. de la Rua-Domenech, R., A. T. Goodchild, H. M. Vordermeier, R. G. Hewinson, K. H. Christiansen, and R. S. Clifton-Hadley. 2006. Antemortem diagnosis of tuberculosis in cattle: a review of the tuberculin tests, gamma-interferon assay and other ancillary diagnostic techniques. Res. Vet. Sci. 81:190–210.

12. Denis, M., D. N. Wedlock, and B. M. Buddle. 2004. Ability of T cell subsets and their soluble mediators to modulate the replication of Mycobacterium bovis in bovine macrophages. Cell. Immunol. 232:1–8.

13. Francis, J., C. L. Choi, and A. J. Frost. 1973. The diagnosis of tuberculosis in cattle with special reference to bovine PPD tuberculosis. Aust. Vet. J. 49:246–251.

14. Frumento, G., R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459–468.

15. Hirsch, C. S., Z. Toossi, C. Othieno, J. L. Johnson, S. K. Schwander, S. Robertson, R. S. Wallis, K. Edmonds, A. Okwera, R. Mugera, P. Peters, and J. J. Elbner. 1999. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J. Infect. Dis. 180:2069–2073.

16. Reference deleted.

17. Jankovic, D., M. C. Kulberg, C. G. Feng, R. S. Goldszmid, C. M. Collazo, M. Wilson, T. A. Wynn, M. Kamanaka, R. A. Flavell, and A. Sher. 2007. Conventional T-bet+FoxP3+ Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204:271–283.

18. Johnson, L., J. Gough, Y. Spencer, G. Hewinson, M. Vordermeier, and A. Wangoo. 2006. Immunohistochemical markers assess augmentation of vaccine efficacy and disease severity in bacillus Calmette-Guerin (BCG) vaccinated cattle challenged with Mycobacterium bovis. Vet. Immunol. Immunopathol. 111:219–229.

19. Reference deleted.

20. Lepper, A. W., C. W. Pearson, and L. A. Corner. 1977. Anergy to tuberculin in beef cattle. Aust. Vet. J. 53:214–216.

21. Reference deleted.

22. Montagnoli, C., F. Fallarino, R. Gaziano, S. Bozza, S. Bellochio, T. Zelante, W. P. Kurup, L. Pitzurra, P.uccietti, and L. Romani. 2006. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J. Immunol. 176:1712–1723.

23. Reference deleted.

24. Olsen, L., P. Boysen, S. Kulberg, J. C. Hope, G. Jungersen, and A. K. Storset. 2005. Bovine NK cells can produce gamma interferon in response to the secreted mycobacterial proteins ESAT-6 and MPPL14 but not in response to MPP70. Infect. Immun. 73:5628–5635.

25. Orme, I. M., M. J. Ratcliffe, and F. M. Collins. 1984. Acquired immunity to heavy infection with Mycobacterium bovis bacillus Calmette-Guerin and its relationship to the development of nonspecific unresponsiveness in vitro. Cell Immunol. 88:285–296.

26. Reference deleted.

27. Reference deleted.

28. Rhodes, S. G., R. G. Hewinson, and H. M. Vordermeier. 2001. Antigen recognition and immunomodulation by gamma delta T cells in bovine tuberculosis. J. Immunol. 166:5604–5610.

29. Rothel, J. S., S. L. Jones, L. A. Corner, J. C. Cox, and P. R. Wood. 1990. A sandwich enzyme immunoassay for bovine interferon-gamma and its use for the detection of tuberculosis in cattle. Aust. Vet. J. 67:134–137.

30. Shimizu, T., C. Sano, and H. Tomioka. 2004. Contact-mediated suppression of T cell mitogenesis by immunosuppressive macrophages induced with mycobacterial infection. Clin. Exp. Immunol. 135:373–379.

31. Turcotte, R., and D. Legault. 1986. Mechanisms underlying the depressed production of interleukin-2 in spleen and lymph node cell cultures of mice infected with Mycobacterium bovis BCG. Infect. Immun. 51:826–831.

32. Reference deleted.

33. Waters, W. R., B. J. Nonnecke, M. V. Palmer, S. Robbe-Austermann, J. P. Bannantine, J. R. Stabel, D. L. Whipple, J. B. Payne, D. M. Estes, J. E. Pitzer, and F. C. Minion. 2004. Use of recombinant ESAT-6:CFP-10 fusion protein for differentiation of infections of cattle by Mycobacterium bovis and by M. avium subsp. avium and M. avium subsp. paratuberculosis. Clin. Diagn. Lab. Immunol. 11:729–735.

34. Waters, W. R., M. V. Palmer, T. C. Thacker, J. B. Payeur, N. B. Harris, F. C. Minion, R. Greenwald, J. Esfandiari, P. Andersen, J. McNair, J. M. Pollock, and K. P. Lyashchenko. 2006. Immune responses to defined antigens of Mycobacterium bovis in cattle experimentally infected with Mycobacterium kansasii. Clin. Vaccine Immunol. 13:611–619.

35. Wedlock, D. N., A. R. McCarthy, E. E. Doolin, S. J. Lacy-Hulbert, M. W. Woolford, and B. M. Buddle. 2004. Effect of recombinant cytokines on leukocytes and physiological changes in bovine mammary glands during early involution. J. Dairy Res. 71:154–161.

36. Widdison, S., L. J. Schreuder, B. Villarreal-Ramos, C. J. Howard, M. Watson, and T. J. Coffey. 2006. Cytokine expression profiles of bovine lymph nodes: effects of Mycobacterium bovis infection and bacille Calmette-Guerin vaccination. Clin. Exp. Immunol. 144:281–289.